Assenagon Asset Management S.A. acquired a new stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 19,183 shares of the biopharmaceutical company’s stock, valued at approximately $2,334,000.
Several other large investors also recently modified their holdings of the company. First Quadrant L P CA acquired a new position in Alexion Pharmaceuticals during the second quarter valued at about $20,860,000. Main Street Research LLC acquired a new position in Alexion Pharmaceuticals during the second quarter valued at about $304,000. Louisiana State Employees Retirement System boosted its position in Alexion Pharmaceuticals by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 13,900 shares of the biopharmaceutical company’s stock valued at $1,691,000 after buying an additional 100 shares during the last quarter. LS Investment Advisors LLC boosted its position in Alexion Pharmaceuticals by 6.6% in the second quarter. LS Investment Advisors LLC now owns 6,533 shares of the biopharmaceutical company’s stock valued at $795,000 after buying an additional 402 shares during the last quarter. Finally, CrestPoint Capital Management LLC acquired a new position in Alexion Pharmaceuticals during the second quarter valued at about $487,000. 95.14% of the stock is owned by hedge funds and other institutional investors.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded up 0.48% on Friday, reaching $132.93. The company had a trading volume of 1,312,700 shares. The stock has a market cap of $29.67 billion, a price-to-earnings ratio of 57.65 and a beta of 1.41. The company has a 50-day moving average of $129.36 and a 200 day moving average of $122.92. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $145.41.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.48. The firm had revenue of $912 million for the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same period last year, the company earned $1.13 EPS. On average, equities research analysts predict that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was reported by BNB Daily and is the property of of BNB Daily. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.baseball-news-blog.com/2017/08/14/19183-shares-in-alexion-pharmaceuticals-inc-nasdaqalxn-acquired-by-assenagon-asset-management-s-a-updated-updated-updated.html.
A number of research analysts have recently weighed in on the company. UBS AG reissued a “buy” rating and issued a $140.00 price target (down from $143.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 31st. Zacks Investment Research raised Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 price target on the stock in a research note on Wednesday, August 2nd. BidaskClub raised Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 5th. BMO Capital Markets reissued an “outperform” rating and issued a $168.00 price target (up from $159.00) on shares of Alexion Pharmaceuticals in a research note on Friday, July 28th. Finally, Jefferies Group LLC set a $120.00 price target on Alexion Pharmaceuticals and gave the stock a “hold” rating in a research note on Thursday, June 8th. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $156.89.
In other Alexion Pharmaceuticals news, Director Bros. Advisors Lp Baker bought 1,348,955 shares of Alexion Pharmaceuticals stock in a transaction on Wednesday, June 14th. The shares were purchased at an average cost of $116.32 per share, for a total transaction of $156,910,445.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $137.74, for a total value of $96,418.00. Following the transaction, the director now owns 6,315 shares in the company, valued at $869,828.10. The disclosure for this sale can be found here. Insiders bought a total of 2,019,734 shares of company stock worth $235,606,846 over the last 90 days. 4.35% of the stock is owned by corporate insiders.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.